Oculus Innovative Sciences
This article was originally published in The Gray Sheet
Executive Summary
Petaluma, Calif., company will launch the first hydrogen version of its Microcyn technology July 1. Microcyn Skin and Wound Hydrogel received FDA clearance in May for management of exuding wounds such as leg ulcers and diabetic ulcers, and for management of mechanically or surgically debrided wounds. In early June, Oculus announced its original Microcyn Skin and Wound Cleaner received 510(k) clearance for debridement of wounds such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, and first- and second-degree burns. During the company's June 11 fourth-quarter earnings call, Oculus CEO Hoji Alimi said studies have shown Microcyn technology to be effective in wound healing, but the company says it is not marketing the product for that claim. Oculus declined to say whether the company would seek a wound healing indication for Microcyn in the future
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.